drugset / Trial / NCT04966832

Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults

NCT04966832 ↗

Phase 1 Completed 84 enrolled XWPharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of XW10508 in healthy volunteers.

Timeline

Start
2021-07-13
Primary completion
2022-06-13
Completion
2022-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject XW10508 Unknown — Oral

Indications

No indication recorded.